Assay and drug development technologies最新文献

筛选
英文 中文
Translational Strategies in Smart Drug Delivery Systems for Controlled and Personalized Pharmacokinetics. 控制和个性化药代动力学的智能药物传递系统的转化策略。
IF 1.8 4区 医学
Assay and drug development technologies Pub Date : 2026-11-03 DOI: 10.1177/1540658X261502046
Chandrashekar Thalluri, Sarad Pawar Naik Bukke, Jharna Medhi, Mallikarjun Vasam, Nithin Vidiyala, Pavani Sunkishala, Kumara Swamy Samanthula
{"title":"Translational Strategies in Smart Drug Delivery Systems for Controlled and Personalized Pharmacokinetics.","authors":"Chandrashekar Thalluri, Sarad Pawar Naik Bukke, Jharna Medhi, Mallikarjun Vasam, Nithin Vidiyala, Pavani Sunkishala, Kumara Swamy Samanthula","doi":"10.1177/1540658X261502046","DOIUrl":"https://doi.org/10.1177/1540658X261502046","url":null,"abstract":"<p><p>\u0000 <i>Advancements in drug delivery systems (DDSs) have developed pharmacotherapy by enabling precise control over drug pharmacokinetics (PKs), enhancing therapeutic efficacy, minimizing toxicity, and improving patient compliance. This review comprehensively examines emerging DDS strategies designed to optimize absorption, distribution, metabolism, and excretion (ADME) of therapeutic agents. Key innovations include nanotechnology-based carriers (liposomes, polymeric nanoparticles, and dendrimers), stimuli-responsive and smart delivery systems, site-specific and tissue-targeted DDS, and prodrug DDS hybrid approaches. Integration of PK modeling, artificial intelligence (AI), and omics data has facilitated personalized and patient-specific therapy, while advanced computational tools allow predictive simulation of drug behavior. Translational challenges such as scale-up, regulatory approval, interpatient variability, long-term safety, and clinical trial design are discussed, alongside strategies to overcome these barriers. Future perspectives emphasize AI-assisted optimization, multimodal DDS combining therapeutic and diagnostic functionalities, biodegradable and sustainable materials, and regenerative and cellular delivery platforms. Collectively, these developments highlight a paradigm shift toward adaptive, precise, and personalized pharmacotherapy, bridging preclinical innovation with clinical application. This review provides a comprehensive framework for understanding the current landscape and future directions of DDS in controlling PKs, ultimately supporting safer and more effective patient-centric therapies.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"1540658X261502046"},"PeriodicalIF":1.8,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formulation, In Vitro and In Vivo Evaluation of Lutein-Myo-Inositol Microspheres in a Letrozole-Induced Rat Model of PCOS. 来曲唑诱导多囊卵巢综合征大鼠模型叶黄素-肌醇微球的制备及体外和体内评价。
IF 1.8 4区 医学
Assay and drug development technologies Pub Date : 2026-11-02 DOI: 10.1177/1540658X261495803
Snigdha Bhardwaj, Nikita Sharma, Khushi Sharma, Kandasamy Nagarajan
{"title":"Formulation, <i>In Vitro</i> and <i>In Vivo</i> Evaluation of Lutein-Myo-Inositol Microspheres in a Letrozole-Induced Rat Model of PCOS.","authors":"Snigdha Bhardwaj, Nikita Sharma, Khushi Sharma, Kandasamy Nagarajan","doi":"10.1177/1540658X261495803","DOIUrl":"https://doi.org/10.1177/1540658X261495803","url":null,"abstract":"<p><p>Polycystic ovary syndrome (PCOS) is a prevalent and complex hormone-metabolic condition that impacts females of reproductive age. Current pharmacological treatments often address limited symptoms, may involve long-term use of synthetic drugs, and are frequently associated with adverse effects and limited patient adherence. In recent years, natural therapeutic agents such as Lutein and Myo-inositol have acquired increasing interest due to their promising biological properties and minimal side effects. Strong antioxidant lutein aids in lowering inflammation and oxidative stress, while Myo-inositol, a naturally occurring sugar alcohol, has insulin-sensitizing and ovulation-inducing effects, making them ideal candidates for addressing the multifaceted pathophysiology of PCOS. Nevertheless, the application of these compounds in therapy is restricted by their limited solubility, reduced bioavailability, and brief half-life. To overcome these challenges, the present research focused on the development and assessment of sustained-release poly-herbal microspheres incorporating Lutein and Myo-inositol using the emulsification method. Nine different formulations (F1 to F9) were prepared and characterized for <i>in vitro</i> parameters. Among the nine formulations developed, one optimized formulation demonstrated high encapsulation efficiency (>90%), satisfactory production yield (>85%), and sustained drug release of approximately 90% over 8 h. In the letrozole-induced PCOS rat model, treatment significantly reduced malondialdehyde (MDA) levels and increased glutathione (GSH) levels compared with the disease control group (<i>p</i> < 0.001). Histopathological evaluation showed a marked reduction in cystic follicles and restoration of normal ovarian morphology in the treated group. Furthermore, <i>in vivo</i> efficacy was confirmed through histopathological examination of ovarian tissues in animal models, where treated groups, especially T3, receiving the highest concentration demonstrated restoration of normal ovarian architecture, reduction in cystic follicles, and improved follicular development. These outcomes support the hypothesis that a combination of Lutein and Myo-inositol, when delivered through a sustained-release microsphere system, can effectively target oxidative stress, insulin resistance, hormonal imbalance, and ovarian dysfunction, which are central to PCOS pathogenesis.</p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"1540658X261495803"},"PeriodicalIF":1.8,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thiolated Natural Gum-Based Drug Delivery Techniques and Their Efficiency in Diabetes Mellitus and Associated Carcinoma: Possibilities, Pathways, Applications, and Challenges. 巯基天然牙龈给药技术及其在糖尿病和相关癌症中的有效性:可能性、途径、应用和挑战。
IF 1.8 4区 医学
Assay and drug development technologies Pub Date : 2026-11-01 Epub Date: 2026-08-30 DOI: 10.1177/1540658X261477914
Diya Zaman Shah, Bani Kumar Jana, Anup Kumar Das, Niva Rani Gogoi, Tumpa Sarkar, Mohini Singh, Bhaskar Mazumder
{"title":"Thiolated Natural Gum-Based Drug Delivery Techniques and Their Efficiency in Diabetes Mellitus and Associated Carcinoma: Possibilities, Pathways, Applications, and Challenges.","authors":"Diya Zaman Shah, Bani Kumar Jana, Anup Kumar Das, Niva Rani Gogoi, Tumpa Sarkar, Mohini Singh, Bhaskar Mazumder","doi":"10.1177/1540658X261477914","DOIUrl":"10.1177/1540658X261477914","url":null,"abstract":"<p><p>\u0000 <i>In the last few decades, diabetes mellitus has become an increasingly prevalent global health crisis. Both type 1 and type 2 diabetes are associated with a wide range of complications, including diabetic retinopathy, neuropathy, nephropathy, cardiovascular disease, and a higher risk of gastrointestinal, liver, and pancreatic cancers. In managing such conditions, drug delivery systems with enhanced therapeutic efficacy and specific tissue targets have received significant attention. Development of thiolated natural gums, which are polysaccharides that have been covalently modified with thiol groups, has paved the way for biomaterial-based drug delivery. These modified polymers are also prominent choices for controlled delivery of active pharmaceutical ingredients in topical application, dry powder inhalation, or oral administration. Additionally, they can enclose hydrophilic macromolecular drugs, peptides, RNA, and biomacromolecules, namely insulin, FGF, and siRNA. This article explores the potential of thiolated natural gums in drug delivery for the treatment of diabetes and diabetes-associated carcinoma. The properties of thiolated gums, their mechanisms of drug release, and their advantages over conventional drug delivery systems are also discussed here. Furthermore, the article delves into various applications for diabetes and diabetes-associated breast, liver, and colorectal cancers. The article also discusses the challenges and future prospects of thiolated natural gums in the pharmaceutical arena.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"589-609"},"PeriodicalIF":1.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Vitro Interaction of Tacrolimus (FK506) with Conventional and Nanoformulated Antifungal Drugs Against Clinical Dermatophyte Isolates Including Trichophyton indotineae. 他克莫司(FK506)与常规及纳米配方抗真菌药物对包括印多毛癣菌在内的临床分离皮肤真菌的体外相互作用
IF 1.8 4区 医学
Assay and drug development technologies Pub Date : 2026-11-01 Epub Date: 2026-08-23 DOI: 10.1177/1540658X261480271
Reihaneh Seiad Ahmadnezhad, Shirin Farahyar, Bita Mehravi, Maryam Roudbary, Romina Ghazi Mirsaid, Sahar Soleymanzadeh, Shahram Mahmoudi
{"title":"<i>In Vitro</i> Interaction of Tacrolimus (FK506) with Conventional and Nanoformulated Antifungal Drugs Against Clinical Dermatophyte Isolates Including <i>Trichophyton indotineae</i>.","authors":"Reihaneh Seiad Ahmadnezhad, Shirin Farahyar, Bita Mehravi, Maryam Roudbary, Romina Ghazi Mirsaid, Sahar Soleymanzadeh, Shahram Mahmoudi","doi":"10.1177/1540658X261480271","DOIUrl":"10.1177/1540658X261480271","url":null,"abstract":"<p><p>\u0000 <i>Dermatophytosis is a global infection with increasing reports of resistance among its causative agents in recent years. As a result of this issue, new therapeutic options are needed. The calcineurin-calmodulin pathway is critical for fungi. Inhibitors of this pathway, such as tacrolimus in combination with antifungal drugs, may serve as alternative treatments. Nanoformulation is another method to address challenges in dermatophytosis treatment. Thirty dermatophyte isolates were included in this study. Antidermatophyte activities of terbinafine, itraconazole, posaconazole, nanoposaconazole, and tacrolimus were investigated using the third edition of the CLSIM38 protocol. <i>In vitro</i> interactions between tacrolimus and the antifungal drugs were studied using a checkerboard method. The isolates included <i>Trichophyton indotineae</i> (<i>n</i> = 14), <i>Trichophyton tonsurans</i> (<i>n</i> = 9), <i>Trichophyton interdigitale</i> (<i>n</i> = 6), and <i>Microsporum canis</i> (<i>n</i> = 1). Tacrolimus demonstrated moderate inhibitory effects against all species. Itraconazole had the strongest activity; however, based on EUCAST epidemiological cutoff values, one <i>T. indotineae</i> isolate was non-wildtype to this drug. Additionally, 10 out of 14 (71.42%) isolates of this species were non-wild type to terbinafine. Nanoposaconazole showed superior antifungal activity compared to posaconazole. Regarding drug combinations, the highest and lowest synergistic rates were observed for combinations of tacrolimus with nanoposaconazole (15/30, 50%) and itraconazole (4/30, 13.33%), respectively. The high rate of non-wildtype <i>T. indotineae</i> isolates to terbinafine underscores the necessity of precise identification to prevent treatment failure. Itraconazole proved to be the most effective antifungal. Combining tacrolimus with antifungal drugs, particularly nanoposaconazole, shows promise and warrants further investigation.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"640-646"},"PeriodicalIF":1.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiangiogenic Effect of Pluchea lanceolata in Adjuvant-Induced Rheumatoid Arthritis in Wistar Rats by Downregulating VEGF Signaling Pathway and Proinflammatory Cytokines. 杉木通过下调VEGF信号通路和促炎细胞因子对佐剂诱导的类风湿关节炎大鼠的抗血管生成作用。
IF 1.8 4区 医学
Assay and drug development technologies Pub Date : 2026-11-01 Epub Date: 2026-08-19 DOI: 10.1177/1540658X261472169
Nimesh Bhardwaj, Praveen Kr Dixit, Kandasamy Nagarajan, Snigdha Bhardwaj
{"title":"Antiangiogenic Effect of <i>Pluchea lanceolata</i> in Adjuvant-Induced Rheumatoid Arthritis in Wistar Rats by Downregulating VEGF Signaling Pathway and Proinflammatory Cytokines.","authors":"Nimesh Bhardwaj, Praveen Kr Dixit, Kandasamy Nagarajan, Snigdha Bhardwaj","doi":"10.1177/1540658X261472169","DOIUrl":"10.1177/1540658X261472169","url":null,"abstract":"<p><p><i>The current work aimed to investigate the therapeutic potential of</i> Pluchea lanceolata <i>(Rasna) in the management of rheumatoid arthritis (RA) using</i> in silico, in vitro, <i>and</i> in vivo <i>studies. After administering Rasna (aqueous and ethanolic extracts), physical parameters such as paw volume and arthritic score were found suppressed in rats (in Freund's complete adjuvant-induced model). Also, radiography and histopathological findings revealed that joint deformities, pannus formation, and tissue swelling of the ankle joint improved when compared with standard and arthritis-induced after 4 weeks. Simultaneously, ELISA results revealed that the serum levels of IL-1β, IL-6, TNF-α, C-reactive protein (CRP), and COL2A1 were lowered when compared with the standard group. An</i> in silico <i>study revealed that quercetin, isorhamnetin, and linalool were the potential active phytoconstituents and showed promising binding affinity toward targets such as KDR (VEGFR2), matrix metalloproteinase (MMPs), ALOX5, IL-1β, IL-6, TNF-α, CRP, and COL2A1. The biological mechanism of Rasna includes several molecular and cellular functions involving the downregulation of angiogenesis through the vascular endothelial growth factor signaling pathway, the MAPK signaling pathway, PI3K-Akt signaling pathway, and the reduction of cytokines and anti-collagen II antibodies. Rasna inhibits the activation of the abovementioned pathways and mRNA expression of IL-1β, IL-6, and TNF-α in RA. The study suggested the potential use of Rasna in managing arthritis treatment over the conventional therapy in immunocompromised patients.</i></p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"610-639"},"PeriodicalIF":1.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineering Quercetin-Loaded Nanostructured Lipid Carriers for Enhanced Oral Delivery: Physicochemical Characterization and In Vitro Antioxidant Evaluation. 工程负载槲皮素的纳米结构脂质载体增强口服递送:理化特性和体外抗氧化评价。
IF 1.8 4区 医学
Assay and drug development technologies Pub Date : 2026-10-30 DOI: 10.1177/1540658X261502041
Komal Saini, Hemant Jethi
{"title":"Engineering Quercetin-Loaded Nanostructured Lipid Carriers for Enhanced Oral Delivery: Physicochemical Characterization and <i>In Vitro</i> Antioxidant Evaluation.","authors":"Komal Saini, Hemant Jethi","doi":"10.1177/1540658X261502041","DOIUrl":"https://doi.org/10.1177/1540658X261502041","url":null,"abstract":"<p><p>\u0000 <i>Depression is a relatively common mental disorder characterized by a severe imbalance of neurotransmitters. Numerous current therapies are available, but they have drawbacks such as limited bioavailability restricted by the blood-brain barrier (BBB). To address the poor aqueous solubility and limited bioavailability of quercetin (Que), Que-loaded nanostructured lipid carriers (Que-NLCs) were developed and evaluated for their physicochemical characteristics, stability, <i>in vitro</i> drug release behavior, and antioxidant activity. Que-loaded NLCs were prepared by probe-sonicator homogenizer and characterized for particle size (167 ± 0.57 nm) and zeta potential (-9.90 ± 0.05 mV). Total drug content and entrapment efficiency were 86.2% ± 2.15% and 98.35% ± 1.35%, respectively. Fourier transform infrared spectroscopy and differential scanning calorimetry studies confirmed drug encapsulation. High-resolution transmission electron microscopy and field emission scanning electron microscopy revealed spherical particle morphology. pH determination and stability studies showed no significant degradative changes. <i>In vitro</i> drug release followed the Korsmeyer-Peppas model, indicating a non-Fickian mechanism. DPPH analysis demonstrated concentration-dependent antioxidant activity of Que-NLCs. These findings demonstrate favorable physicochemical, release, stability, and antioxidant characteristics of Que-NLCs; however, further studies are required to establish their BBB permeability and therapeutic potential for neurological applications.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"1540658X261502041"},"PeriodicalIF":1.8,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149294395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Central Composite Design Approach Stability-Indicating RP-HPLC Analysis for Simultaneous Estimation of Monoclonal Antibodies in Bulk and Combined Dosage Form. 中心复合设计方法稳定性指示的反相高效液相色谱法同时测定单克隆抗体原料药和联合剂型。
IF 1.8 4区 医学
Assay and drug development technologies Pub Date : 2026-10-23 DOI: 10.1177/1540658X261500557
Anusha Gandi, Srinivasa Rao Yarguntla, BhaskaraRao Pulagurtha, Lakshmi Durga Bhavani Nuziveeti
{"title":"Central Composite Design Approach Stability-Indicating RP-HPLC Analysis for Simultaneous Estimation of Monoclonal Antibodies in Bulk and Combined Dosage Form.","authors":"Anusha Gandi, Srinivasa Rao Yarguntla, BhaskaraRao Pulagurtha, Lakshmi Durga Bhavani Nuziveeti","doi":"10.1177/1540658X261500557","DOIUrl":"https://doi.org/10.1177/1540658X261500557","url":null,"abstract":"<p><p>\u0000 <i>This study presents the novel quality by design (QbD)-assisted RP-HPLC method for the simultaneous estimation of relatlimab and nivolumab in both bulk and pharmaceutical formulations, utilizing a statistically optimized design via central composite design (CCD). Optimization was performed by CCD by selecting mobile phase ratio of acetonitrile, pH of buffer, and flow rate as factors and evaluating responses, namely retention time and tailing factor, through Waters Alliance-e2695, which occurred using a Kromasil C18 (150 × 4.6 mm, 3.5 µm) column that operated with a mobile phase composed of acetonitrile:ammonium acetate in the ratio of 20:80 v/v. The detector used a photodiode array for absorbance-based reading at 236 nm with an ambient temperature setup. The detection system worked at 1.0 mL/min flow rates. The results obtained from the validation parameters demonstrate that this RP-HPLC method, developed using the QbD approach, is robust and dependable. ICH guidelines served as the basis for conducting the validation of this proposed method. Forced degradation is carried out at various stress conditions. The method offers a rapid, robust, and cost-effective analytical solution with high precision and accuracy, validated as per ICH guidelines, and is well-suited for routine quality control and stability studies.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"1540658X261500557"},"PeriodicalIF":1.8,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Yi-Qi-Bu-Shen Recipe Alleviates Diabetic Peripheral Neuropathy: Network Pharmacology Prediction and In Vivo Evidence. 益气补肾方减轻糖尿病周围神经病变:网络药理学预测及体内证据。
IF 1.8 4区 医学
Assay and drug development technologies Pub Date : 2026-10-22 DOI: 10.1177/1540658X261496344
Yuanyuan Liu, Yingying Zhao, Fengbo Wu, Yan Zhu, Chuanqian Liu
{"title":"Yi-Qi-Bu-Shen Recipe Alleviates Diabetic Peripheral Neuropathy: Network Pharmacology Prediction and <i>In Vivo</i> Evidence.","authors":"Yuanyuan Liu, Yingying Zhao, Fengbo Wu, Yan Zhu, Chuanqian Liu","doi":"10.1177/1540658X261496344","DOIUrl":"https://doi.org/10.1177/1540658X261496344","url":null,"abstract":"<p><p>\u0000 <i>Diabetic peripheral neuropathy (DPN) is a common chronic complication of diabetes that severely impairs quality of life. The Yi-Qi-Bu-Shen Recipe (YQBS) alleviates diabetic complications, but its mechanism against DPN remains unclear. This study aimed to explore the underlying mechanism of YQBS against DPN using network pharmacology and to verify its effects on peripheral nerve injury and modulation of the AGE-RAGE/NF-κB signaling pathway <i>in vivo</i>. Active components of YQBS were computationally screened <i>via</i> the TCMSP database, potential targets were predicted using GeneCards and OMIM, and key pathways were analyzed by KEGG enrichment. Molecular docking was performed to assess binding affinities. In animal experiments, streptozotocin-induced DPN rats were randomized into control, model, low-dose YQBS, and high-dose YQBS groups. After 12 weeks, nerve conduction velocity, sciatic nerve pathology, nerve repair-related proteins, and RAGE/NF-κB p65 phosphorylation were evaluated. Network pharmacology predicted quercetin, β-sitosterol, and formononetin as major active components, <i>PTGS2</i> and <i>NOS2</i> as core targets, and AGE-RAGE/PI3K-Akt as key pathways. Molecular docking predicted favorable binding affinities. Animal experiments confirmed that YQBS significantly improved nerve conduction, alleviated nerve damage, upregulated repair proteins, and inhibited RAGE expression and NF-κB p65 phosphorylation. In conclusion, YQBS ameliorates DPN in rats, with suppression of AGE-RAGE/NF-κB pathway activation.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"1540658X261496344"},"PeriodicalIF":1.8,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deguelin Alleviates Renal Tubular Epithelial Cell Injury in Lupus Nephritis by Inhibiting the PI3K/Akt Signaling Pathway. 去桂林通过抑制PI3K/Akt信号通路减轻狼疮性肾炎肾小管上皮细胞损伤
IF 1.8 4区 医学
Assay and drug development technologies Pub Date : 2026-10-12 DOI: 10.1177/1540658X261494333
Shiling Zhong, Xunwei Liu, Yunyan Li, Wenying Hao, Yuanling Chen, Jika Zheng, Ling Wu
{"title":"Deguelin Alleviates Renal Tubular Epithelial Cell Injury in Lupus Nephritis by Inhibiting the PI3K/Akt Signaling Pathway.","authors":"Shiling Zhong, Xunwei Liu, Yunyan Li, Wenying Hao, Yuanling Chen, Jika Zheng, Ling Wu","doi":"10.1177/1540658X261494333","DOIUrl":"https://doi.org/10.1177/1540658X261494333","url":null,"abstract":"<p><p>\u0000 <i>Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus. Circadian rhythm disorders are related to the pathogenesis of LN. This study aims to identify the core circadian rhythm-related genes in LN and identify the potential natural active compounds for LN treatment. In the present study, cyclin A2 (CCNA2) and cyclin-dependent kinase inhibitor 3 (CDKN3) were identified as the core targets most related to the circadian rhythm of LN. Both of them were upregulated in blood and kidney tissue samples in LN and had high diagnostic efficacy. Deguelin had strong binding capabilities with CCNA2 and CDKN3 proteins. Deguelin could dose-dependently alleviate lipopolysaccharide-induced human kidney-2 (HK-2) cell damage, inhibit cell apoptosis and the release of inflammatory factors, downregulate the mRNA and protein expression levels of core genes CCNA2 and CDKN3, and inhibit the activation of the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. The protective effect of deguelin could be reversed by AKT activator SC79 treatment. In summary, CCNA2 and CDKN3 are core genes related to the circadian rhythm in LN. Deguelin probably alleviates renal tubular epithelial cell injury by modulating the expression levels of core genes CCNA2 and CDKN3, inhibiting the activation of the PI3K/Akt signaling pathway, and thus has the potential to become a therapeutic agent for LN.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"1540658X261494333"},"PeriodicalIF":1.8,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting Quorum Sensing LsrR Protein in E. coli: A Computational Approach to Screen the Plant Bioactive Compounds as Inhibitors of Biofilm Formation in Urinary Tract Infections. 在大肠杆菌中靶向群体感应LsrR蛋白:筛选作为尿路感染生物膜形成抑制剂的植物生物活性化合物的计算方法。
IF 1.8 4区 医学
Assay and drug development technologies Pub Date : 2026-10-01 Epub Date: 2026-03-23 DOI: 10.1177/1540658X261429261
Sitrarasu Vijaya Prabhu, Shreya Suman, Alagu Chellapandi, Padmalochani Baskaradoss, Sivan Padma Priya, Thilakavathy Pandurangan, Muniappan Ayyanar, Rengarajan Murugesan, Prabhu Srinivasan
{"title":"Targeting Quorum Sensing LsrR Protein in <i>E. coli:</i> A Computational Approach to Screen the Plant Bioactive Compounds as Inhibitors of Biofilm Formation in Urinary Tract Infections.","authors":"Sitrarasu Vijaya Prabhu, Shreya Suman, Alagu Chellapandi, Padmalochani Baskaradoss, Sivan Padma Priya, Thilakavathy Pandurangan, Muniappan Ayyanar, Rengarajan Murugesan, Prabhu Srinivasan","doi":"10.1177/1540658X261429261","DOIUrl":"10.1177/1540658X261429261","url":null,"abstract":"<p><p>\u0000 <i>Antimicrobial resistance (AMR) in <i>Escherichia coli</i>, driven by biofilm formation and quorum sensing (QS), presents a significant challenge in combating infections, particularly urinary tract infections. This study explored the potential of plant bioactive compounds to inhibit LsrR, a key transcriptional regulator of the QS system, in <i>E. coli</i>. The active site of LsrR was identified using the Sitemap module, which demonstrated high druggability, with a D-score of 0.987. Structure-based virtual screening was used to identify plant-derived inhibitors, followed by docking, binding free energy calculations, and induced-fit docking to evaluate ligand interactions and stability. Chebulinic acid, rutin, and vicine have emerged as potent inhibitors with better docking scores and multiple protein-ligand interactions. Molecular dynamics simulations confirmed the stability of these complexes, highlighting their potential to disrupt QS pathways and inhibit bacterial biofilm formation. These findings suggest that plant bioactive compounds are promising novel therapeutic agents for mitigating AMR in <i>E. coli</i> by targeting LsrR.</i>\u0000 </p>","PeriodicalId":8586,"journal":{"name":"Assay and drug development technologies","volume":" ","pages":"517-537"},"PeriodicalIF":1.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书